Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/22/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Scott A. Siegel Ph.D.

Wrong Dr. Scott A. Siegel Ph.D.?

Managing Director

Local Address: New York City, New York, United States
Milestone Life Sciences, LLC
 
Background

Employment History

Education

  • Ph.D. , biochemistry
    State University of New York
  • Bachelor of Science degree , biology
    State University of New York , College at New Paltz
  • Yale University School of Medicine
39 Total References
Web References
Ezose Sciences Inc.
www.ezosesciences.com, 8 July 2013 [cached]
Scott A. Siegel, Ph.D. Chief Operating Officer
Dr. Scott Siegel serves as Ezose Sciences' Chief Operating Officer and head of Business Development, bringing over 25 years experience in the biotechnology and pharmaceutical industries to the role. Prior to joining Ezose he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company based in NJ. Previously, he spent eight years with Johnson & Johnson in both New Business Development and Worldwide Strategic Marketing, with responsibilities for the in-licensing of new pharmaceutical products and technologies. Earlier in his career he served in various R&D capacities including Senior Director, Preclinical Research and Development for Phytera, Inc.; Associate Director, Immunobiology Research for Centocor, Inc.; and Section Leader, Immunodiagnostics Development for Becton Dickinson and Co. He also previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade® (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders. He earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
Rx Communications Group, LLC
www.rxir.com, 1 Oct 2007 [cached]
REDPOINT BIO NAMES SCOTT SIEGEL, PH.D. AS VICE PRESIDENT OF CORPORATE DEVELOPMENT Rx Communications Group, LLC
...
REDPOINT BIO NAMES SCOTT SIEGEL, PH.D. AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
Ewing, New Jersey, October 1, 2007 - Redpoint Bio Corporation (OTCBB: RPBC), a company developing compounds to improve the taste of pharmaceutical, food and beverage products, today announced the appointment of Scott A. Siegel, Ph.D., to the position of Vice President of Corporate Development. In his new role, Dr. Siegel will be responsible for the Company's business development strategy and execution and will report directly to Dr. Ray Salemme, Chief Executive Officer.
...
Commenting on today's news, Dr. Salemme noted, "We are delighted to welcome Scott to Redpoint in this key position.
...
With over 20 years of commercial, business development, and research and development expertise with a broad array of life sciences companies, Scott brings to Redpoint a truly well-rounded set of capabilities. We intend to leverage all of these as we move forward aggressively with product development and additional partnership opportunities for our taste enhancer and bitter blocker programs."
Prior to joining Redpoint Bio, Dr. Siegel, 50, spent eight years with Johnson & Johnson, most recently as Worldwide Strategic Marketing New Business Development Director, with responsibility for commercial review of global oncology therapeutics licensing opportunities. In this capacity, he lead the establishment of a worldwide business case for deals by creating and leading cross-functional assessment teams consisting of Johnson & Johnson affiliates located across the globe.
Before that, Dr. Siegel served in various positions, including Executive Director, New Business Development and Senior Director, at Ortho Biotech Products, L.P., also a Johnson & Johnson affiliate. While there, Dr. Siegel was responsible for new business development strategy and technology assessment with a focus in the areas of drug delivery and lifecycle management, among others. While at Ortho Biotech he lead or played a key role in the transaction and execution of several licensing agreements with US and international business partners.
Earlier in his career, Dr. Siegel served as Senior Director, Preclinical Research and Product Development for Phytera, Inc.; Associate Director, Immunobiology Research and Development for Centocor, Inc., and; Section Leader, Immunodiagnostics Department at Becton Dickinson and Company. He also served, from 1988 to 1995, as Adjunct Associate Professor of Microbiology at the University of Pennsylvania, School of Dental Medicine.
Dr. Siegel earned his Bachelor of Science degree from the State University of New York, College at New Paltz, where he majored in biology. Dr. Siegel also earned a Ph.D. in biochemistry from the State University of New York, Downstate Medical Center and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
Dr. Siegel is a co-inventor of Remicade®, a drug used to treat autoimmune disorders. He is the author of more than 30 scientific and business abstracts and publications, holds 12 issued patents and is a frequent speaker and panel moderator on issues relating to drug delivery, business development and business strategy for the Pharmaceutical and Biotechnology industries.
Glycomics, Biomarker Research, Glycan Analysis – Ezose Sciences Management
www.ezosesciences.com, 17 Jan 2012 [cached]
Scott A. Siegel, Ph.D. Vice President, Business Development
Dr. Scott Siegel serves as Ezose's Sciences Vice President of Business Development, bringing 25 years experience in the biotechnology and pharmaceutical industries to the role. Prior to joining Ezose he was Vice President of Corporate Development for Redpoint Bio, a publicly traded biotechnology company based in NJ. Previously, he spent eight years with Johnson & Johnson in both New Business Development and Worldwide Strategic Marketing, with responsibilities for the in-licensing of new pharmaceutical products and technologies. Prior to joining J&J he served in various R&D capacities including Senior Director, Preclinical Research and Development for Phytera, Inc.; Associate Director, Immunobiology Research for Centocor, Inc.; and Section Leader, Immunodiagnostics Development for Becton Dickinson and Co. He previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania.
Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at the Yale University School of Medicine.
Glycomics, Biomarker Research, Glycan Analysis - Ezose Sciences Management
www.ezosesciences.com, 17 Jan 2012 [cached]
Scott A. Siegel, Ph.D. Vice President, Business Development
Dr. Scott Siegel serves as Ezose Sciences Vice President of Business Development, bringing over 25 years experience in the biotechnology and pharmaceutical industries to the role. Prior to joining Ezose he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company based in NJ. Previously, he spent eight years with Johnson & Johnson in both New Business Development and Worldwide Strategic Marketing, with responsibilities for the in-licensing of new pharmaceutical products and technologies. Prior to joining J&J he served in various R&D capacities including Senior Director, Preclinical Research and Development for Phytera, Inc.; Associate Director, Immunobiology Research for Centocor, Inc.; and Section Leader, Immunodiagnostics Development for Becton Dickinson and Co. He previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania.
Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at the Yale University School of Medicine.
MS-UK | Biomarkers and MicroRNA
www.ms-uk.org, 16 Aug 2012 [cached]
"In its support of biotechnology companies, Fast Forward is establishing a model to combine the innovation of researchers in industry with the insights of leading physician-scientists at academic medical centers," said Scott A. Siegel, Ph.D., Chief Operating Officer of Ezose.
Other People with the name "Siegel":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304